Revenue Showdown: ACADIA Pharmaceuticals Inc. vs Dynavax Technologies Corporation

Biotech Revenue Battle: ACADIA vs. Dynavax

__timestampACADIA Pharmaceuticals Inc.Dynavax Technologies Corporation
Wednesday, January 1, 201412000011032000
Thursday, January 1, 2015610004050000
Friday, January 1, 20161733100011043000
Sunday, January 1, 2017124901000327000
Monday, January 1, 20182238070008198000
Tuesday, January 1, 201933907600035219000
Wednesday, January 1, 202044175500046551000
Friday, January 1, 2021484145000439442000
Saturday, January 1, 2022517235000722683000
Sunday, January 1, 2023726437000232284000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Showdown: A Tale of Two Biotechs

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, ACADIA Pharmaceuticals Inc. and Dynavax Technologies Corporation have been on divergent paths. Starting in 2014, ACADIA's revenue was a mere fraction of Dynavax's, but by 2023, ACADIA's revenue surged by over 6000%, reaching a peak of approximately $726 million. In contrast, Dynavax experienced a rollercoaster ride, with its revenue peaking in 2022 at around $723 million before dropping by nearly 68% in 2023. This dramatic shift highlights ACADIA's impressive growth trajectory, while Dynavax faces challenges in maintaining its revenue momentum. The data underscores the dynamic nature of the biotech industry, where innovation and market adaptation are crucial for sustained success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025